ALERCELL
Alercell is an innovative company focused on revolutionizing cancer prevention and early detection through theranostics and AI. They specialize in developing advanced genetic detection technologies for early identification of cancer and leukemia. Their key products include LENA Q51®, which detects 51 gene mutations, and LENA S1, designed for pre-symptomatic identification of lung cancer. Alercell also offers the LENA Molecular Dx Leukemia Platform. The company leverages AI to create precise biomarkers for the earliest possible cancer detection, aiming to 'stop it before it starts'. Alercell's growth is driven by internal research, strategic alliances, and a passion for genetics and AI.
ALERCELL
Alercell is an innovative company focused on revolutionizing cancer prevention and early detection through theranostics and AI. They specialize in developing advanced genetic detection technologies for early identification of cancer and leukemia. Their key products include LENA Q51®, which detects 51 gene mutations, and LENA S1, designed for pre-symptomatic identification of lung cancer. Alercell also offers the LENA Molecular Dx Leukemia Platform. The company leverages AI to create precise biomarkers for the earliest possible cancer detection, aiming to 'stop it before it starts'. Alercell's growth is driven by internal research, strategic alliances, and a passion for genetics and AI.